4h84 › Citations

Crystallization of bi-functional ligand protein complexes.

Antoni C, Vera L, Devel L, Catalani MP, Czarny B, Cassar-Lajeunesse E, Nuti E, Rossello A, Dive V, Stura EA
J Struct Biol 182 246-54 (2013)
Related entries: 4h1q, 4h2e, 4h30, 4h3x, 4h49, 4h76, 4h82, 4hma, 4i03

Cited: 33 times
EuropePMC logo PMID: 23567804

Abstract

Homodimerization is important in signal transduction and can play a crucial role in many other biological systems. To obtaining structural information for the design of molecules able to control the signalization pathways, the proteins involved will have to be crystallized in complex with ligands that induce dimerization. Bi-functional drugs have been generated by linking two ligands together chemically and the relative crystallizability of complexes with mono-functional and bi-functional ligands has been evaluated. There are problems associated with crystallization with such ligands, but overall, the advantages appear to be greater than the drawbacks. The study involves two matrix metalloproteinases, MMP-12 and MMP-9. Using flexible and rigid linkers we show that it is possible to control the crystal packing and that by changing the ligand-enzyme stoichiometric ratio, one can toggle between having one bi-functional ligand binding to two enzymes and having the same ligand bound to each enzyme. The nature of linker and its point of attachment on the ligand can be varied to aid crystallization, and such variations can also provide valuable structural information about the interactions made by the linker with the protein. We report here the crystallization and structure determination of seven ligand-dimerized complexes. These results suggest that the use of bi-functional drugs can be extended beyond the realm of protein dimerization to include all drug design projects.

Reviews - 4h84 mentioned but not cited (3)

  1. HLA-G Neo-Expression on Tumors. Loustau M, Anna F, Dréan R, Lecomte M, Langlade-Demoyen P, Caumartin J. Front Immunol 11 1685 (2020)
  2. HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges. Lin A, Yan WH. Front Immunol 12 698677 (2021)
  3. Natural Killer Cell Receptors and Endometriosis: A Systematic Review. Reis JL, Rosa NN, Ângelo-Dias M, Martins C, Borrego LM, Lima J. Int J Mol Sci 24 331 (2022)

Articles - 4h84 mentioned but not cited (6)

  1. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. J Exp Med 186 289-298 (1997)
  2. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Tronik-Le Roux D, Renard J, Vérine J, Renault V, Tubacher E, LeMaoult J, Rouas-Freiss N, Deleuze JF, Desgrandschamps F, Carosella ED. Mol Oncol 11 1561-1578 (2017)
  3. Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. HoWangYin KY, Loustau M, Wu J, Alegre E, Daouya M, Caumartin J, Sousa S, Horuzsko A, Carosella ED, LeMaoult J. Cell Mol Life Sci 69 4041-4049 (2012)
  4. Expression of cancer-testis (CT) antigens in placenta. Jungbluth AA, Silva WA, Iversen K, Frosina D, Zaidi B, Coplan K, Eastlake-Wade SK, Castelli SB, Spagnoli GC, Old LJ, Vogel M. Cancer Immun 7 15 (2007)
  5. Clinical Significance of Potential Unidentified HLA-G Isoforms Without α1 Domain but Containing Intron 4 in Colorectal Cancer Patients. Lin A, Zhang X, Zhang RL, Zhang JG, Zhou WJ, Yan WH. Front Oncol 8 361 (2018)
  6. Bronchial Epithelial Cells from Asthmatic Patients Display Less Functional HLA-G Isoform Expression. Carlini F, Picard C, Garulli C, Piquemal D, Roubertoux P, Chiaroni J, Chanez P, Gras D, Di Cristofaro J. Front Immunol 8 6 (2017)


Reviews citing this publication (2)

  1. Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development. Sasikumar PG, Ramachandra M. Front Immunol 13 752065 (2022)
  2. Developments in Carbohydrate-Based Metzincin Inhibitors. Cuffaro D, Nuti E, D'Andrea F, Rossello A. Pharmaceuticals (Basel) 13 E376 (2020)

Articles citing this publication (22)

  1. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Eckhard U, Huesgen PF, Schilling O, Bellac CL, Butler GS, Cox JH, Dufour A, Goebeler V, Kappelhoff R, Keller UAD, Klein T, Lange PF, Marino G, Morrison CJ, Prudova A, Rodriguez D, Starr AE, Wang Y, Overall CM. Matrix Biol 49 37-60 (2016)
  2. Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors. Nuti E, Cuffaro D, D'Andrea F, Rosalia L, Tepshi L, Fabbi M, Carbotti G, Ferrini S, Santamaria S, Camodeca C, Ciccone L, Orlandini E, Nencetti S, Stura EA, Dive V, Rossello A. ChemMedChem 11 1626-1637 (2016)
  3. Preparation and Evaluation of Chitosan/PVA Based Hydrogel Films Loaded with Honey for Wound Healing Application. Chopra H, Bibi S, Kumar S, Khan MS, Kumar P, Singh I. Gels 8 111 (2022)
  4. H3K27me1 is essential for MMP-9-dependent H3N-terminal tail proteolysis during osteoclastogenesis. Kim K, Shin Y, Kim J, Ulmer TS, An W. Epigenetics Chromatin 11 23 (2018)
  5. Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage. Kim Y, Kim J, Lee H, Shin WR, Lee S, Lee J, Park JI, Jhun BH, Kim YH, Yi SJ, Kim K. Int J Mol Sci 20 E4038 (2019)
  6. Optical imaging of MMP-12 active form in inflammation and aneurysm. Razavian M, Bordenave T, Georgiadis D, Beau F, Zhang J, Golestani R, Toczek J, Jung JJ, Ye Y, Kim HY, Han J, Dive V, Devel L, Sadeghi MM. Sci Rep 6 38345 (2016)
  7. kGCN: a graph-based deep learning framework for chemical structures. Kojima R, Ishida S, Ohta M, Iwata H, Honma T, Okuno Y. J Cheminform 12 32 (2020)
  8. A QSAR study on the inhibition mechanism of matrix metalloproteinase-12 by arylsulfone analogs based on molecular orbital calculations. Hitaoka S, Chuman H, Yoshizawa K. Org Biomol Chem 13 793-806 (2015)
  9. Bivalent Inhibitor with Selectivity for Trimeric MMP-9 Amplifies Neutrophil Chemotaxis and Enables Functional Studies on MMP-9 Proteoforms. Nuti E, Rossello A, Cuffaro D, Camodeca C, Van Bael J, van der Maat D, Martens E, Fiten P, Pereira RVS, Ugarte-Berzal E, Gouwy M, Opdenakker G, Vandooren J. Cells 9 E1634 (2020)
  10. Multicomponent mixtures for cryoprotection and ligand solubilization. Ciccone L, Vera L, Tepshi L, Rosalia L, Rossello A, Stura EA. Biotechnol Rep (Amst) 7 120-127 (2015)
  11. Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization. Nuti E, Rosalia L, Cuffaro D, Camodeca C, Giacomelli C, Da Pozzo E, Tuccinardi T, Costa B, Antoni C, Vera L, Ciccone L, Orlandini E, Nencetti S, Dive V, Martini C, Stura EA, Rossello A. ACS Med Chem Lett 8 293-298 (2017)
  12. Inhibition of bacterial and human zinc-metalloproteases by bisphosphonate- and catechol-containing compounds. Rahman F, Nguyen TM, Adekoya OA, Campestre C, Tortorella P, Sylte I, Winberg JO. J Enzyme Inhib Med Chem 36 819-830 (2021)
  13. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products. Gao Q, Wang Y, Hou J, Yao Q, Zhang J. J Comput Aided Mol Des 31 625-641 (2017)
  14. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases. Sylte I, Dawadi R, Malla N, von Hofsten S, Nguyen TM, Solli AI, Berg E, Adekoya OA, Svineng G, Winberg JO. PLoS One 13 e0200237 (2018)
  15. Functional network analysis reveals potential repurposing of β-blocker atenolol for pancreatic cancer therapy. Hermawan A, Putri H, Utomo RY. Daru 28 685-699 (2020)
  16. Biodistribution of Nanostructured Lipid Carriers in Mice Atherosclerotic Model. Devel L, Almer G, Cabella C, Beau F, Bernes M, Oliva P, Navarro F, Prassl R, Mangge H, Texier I. Molecules 24 E3499 (2019)
  17. Design, Synthesis, and Biological Evaluation of Tetrahydro-β-carboline Derivatives as Selective Sub-Nanomolar Gelatinase Inhibitors. Mangiatordi GF, Guzzo T, Rossano EC, Trisciuzzi D, Alberga D, Fasciglione G, Coletta M, Topai A, Nicolotti O. ChemMedChem 13 1343-1352 (2018)
  18. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. Cuffaro D, Camodeca C, Tuccinardi T, Ciccone L, Bartsch JW, Kellermann T, Cook L, Nuti E, Rossello A. ACS Med Chem Lett 12 1787-1793 (2021)
  19. Computer-Aided Screening and Revealing Action Mechanism of Food-Derived Tripeptides Intervention in Acute Colitis. Ge H, Zhang T, Tang Y, Zhang Y, Yu Y, Men F, Liu J, Yu Y. Int J Mol Sci 23 13471 (2022)
  20. Ethyl gallate isolated from phenol-enriched fraction of Caesalpinia mimosoides Lam. Promotes cutaneous wound healing: a scientific validation through bioassay-guided fractionation. Bhat P, Patil VS, Anand A, Bijjaragi S, Hegde GR, Hegde HV, Roy S. Front Pharmacol 14 1214220 (2023)
  21. Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening. Gimeno A, Cuffaro D, Nuti E, Ojeda-Montes MJ, Beltrán-Debón R, Mulero M, Rossello A, Pujadas G, Garcia-Vallvé S. Molecules 26 4553 (2021)
  22. Mechanistic insight into hydroxamate transfer reaction mimicking the inhibition of zinc-containing enzymes. Kwon N, Suh JM, Lim MH, Hirao H, Cho J. Chem Sci 11 9017-9021 (2020)


Related citations provided by authors (1)

  1. Crystallization of bi-functional ligand protein complexes.. Antoni C, Vera L, Devel L, Catalani MP, Czarny B, Cassar-Lajeunesse E, Nuti E, Rossello A, Dive V, Stura EA J Struct Biol 182 246-54 (2013)

Quick links